Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7351 to 7365 of 8221 results

  1. Pelareorep for untreated pancreatic cancer [ID1074]

    Discontinued Reference number: GID-TA10689

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development Reference number: GID-TA10696 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued Reference number: GID-TA10697

    Technology appraisal guidance
    Discontinued

  4. Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

    Discontinued Reference number: GID-TA10698

    Technology appraisal guidance
    Discontinued

  5. Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

    Discontinued Reference number: GID-TA10702

    Technology appraisal guidance
    Discontinued

  6. Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]

    Discontinued Reference number: GID-TA10707

    Technology appraisal guidance
    Discontinued

  7. Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

    Discontinued Reference number: GID-TA10709

    Technology appraisal guidance
    Discontinued

  8. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

    Technology appraisal guidance
    Discontinued

  9. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development Reference number: GID-TA11070 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Terevalefim for treating delayed graft function after kidney transplant [ID1490]

    Discontinued Reference number: GID-TA11098

    Technology appraisal guidance
    Discontinued

  12. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

    Technology appraisal guidance
    Discontinued

  13. Ramucirumab for untreated HER2-negative metastatic gastric or gastro-oesophageal junction cancer [ID1373]

    Discontinued Reference number: GID-TA11120

    Technology appraisal guidance
    Discontinued

  14. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued Reference number: GID-TA11151

    Technology appraisal guidance
    Discontinued

  15. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development Reference number: GID-TA11157 Expected publication date: TBC

    Technology appraisal guidance
    In development